Contact
Reach the editors
Citation errors, broken links, new research, and editorial feedback — this is the channel for those. Not for sourcing, clinical advice, or prescriptions.
What we respond to
Three kinds of message move this chronicle forward:
Citation errors or broken links. If a study's DOI resolves to the wrong paper, a PubMed link is dead, or a cited figure doesn't match its source, send the correction. It will be verified and fixed.
New research. If a retatrutide Phase 2 or Phase 3 result has published and isn't reflected here yet, a link to the primary paper is welcome.
Editorial feedback. If a page overstates the evidence, misreads the research, or mischaracterizes the compound's regulatory status, that note is taken seriously.
What we cannot respond to
This is a chronicle, not a clinic, and no clinician staffs it. Questions about personal health decisions, dosing, whether to try retatrutide, where to find it, or how it interacts with a specific medication cannot be answered here — not out of secrecy, but because those questions need a clinician who knows the person asking.
Requests to source, purchase, or 'order' retatrutide get no reply; the site sells nothing and refers to no seller. Press pitches, partnership proposals, and link-exchange requests are not answered either.
Send a message
Write to the editorial desk to send a note. Include the page URL and the claim in question when reporting an error; include a DOI or PubMed link when submitting new research.
Editorial mailbox: editors@retatrutideorder.com
Response time: Corrections are reviewed periodically, with no guaranteed timeline. When one is confirmed, the relevant page is updated — the change shows up in the page itself, without a separate confirmation email.